Research workbench
Crystal structure of peptide transporter pot (E310Q mutant) in complex with alafosfalin
Analyse Crystal structure of peptide transporter pot (E310Q mutant) in complex with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 4IKZ
- Type
- protein
- Length
- 485 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Di-tripeptide ABC transporter (permease)
- Ligands
- AFS, SO4
- Pockets
- 4 · best druggability 0.76
Structure
x-ray diffraction · 1 distinct chain · 79% helix, 2% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Di-tripeptide ABC transporter (permease) | protein | 485 | 79% helix, 2% strand | — |
Ligands and binding sites
- AFS · N-[(1R)-1-phosphonoethyl]-L-alaninamide · ligand · chains A
- SO4 · Sulfate ion · ion · 6 copies · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 777 | 0.76 | 0.80 | 70 | AFS |
| 2 | 124 | 0.47 | 0.78 | 25 | empty |
| 3 | 112 | 0.40 | 0.75 | 21 | empty |
| 4 | 72 | 0.37 | 0.76 | 12 | empty |
Compared structures
- 4IKZ · Crystal structure of peptide transporter POT (E310Q mutant) in complex with alafosfalin · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Elsewhere: RCSB PDB 4IKZ · PDBe 4IKZ
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.